The IBD clinic nurse’s communication challenge
The IBD clinic nurse works in a specialty where the gap between what the patient experiences and what the disease is doing is systematically large. Inflammatory bowel disease — Crohn’s disease and ulcerative colitis — produces its most dangerous consequences through processes that are invisible to the patient: transmural inflammation driving progressive fibrosis, dysplastic transformation of chronically inflamed mucosa, pharmacologically induced endocrine changes that have nothing to do with the underlying bowel disease. The patient who feels well has no subjective access to any of these processes. The IBD clinic nurse must bridge the gap between the patient’s experience (symptom remission, feeling normal, wanting to simplify treatment) and the disease biology (ongoing inflammation below the symptom threshold, invisible premalignant change, steroid-induced adrenal suppression that persists after the disease is controlled).
Three communication failures recur across the IBD clinic with particular frequency in the Spanish-speaking patient population, where the explanatory framework for inflammatory bowel disease is often less established than in patient communities with longer access to specialist gastroenterological care.
The first occurs when a patient with Crohn’s disease is escalated from mesalamine to a biologic despite feeling well. The logic of “if it works, don’t change it” is sound in most medical contexts and fails specifically in Crohn’s disease because it assumes that symptom control and disease control are the same thing. They are not. Mesalamine cannot reach the transmural inflammation of Crohn’s disease, and a patient who feels well on mesalamine may be accumulating the mucosal and submucosal damage that will manifest as a stricture or fistula years later. The escalation is not a sign that the treatment failed — it is a sign that the assessment became more complete.
The second occurs when a patient with long-standing ulcerative colitis in clinical remission is scheduled for surveillance colonoscopy. The family’s reasoning — she has no symptoms, she is fine, what could a colonoscopy show that a clinical assessment does not — fails because UC-associated dysplasia is endoscopically occult and symptomatically silent. Surveillance colonoscopy is not a response to a clinical problem; it is the detection tool for a pathological process that the patient cannot feel.
The third occurs when a patient wants to stop prednisone after a flare has resolved. This is not about the IBD at all — it is about the endocrine system. But because the prednisone was prescribed for the IBD, the family concludes that when the IBD is controlled, the prednisone is no longer needed. The HPA axis suppression is an independent biological fact that persists after Crohn’s remission, and explaining it requires teaching a physiological system the family has never needed to think about before.
Three conversations from the IBD clinic:
Scenario 1: Pedro Vásquez-Morales — 38, construction project manager from Houston, Texas
Pedro Vásquez-Morales had managed construction projects across the Houston metro for fourteen years, and he approached his health the same way he approached a project: find the problem, apply the correct solution, confirm the result, move on. When he had been diagnosed with Crohn’s disease two years earlier — at the end of a three-month evaluation that had begun with intermittent cramping, fatigue, and what he had described to his internist as “stomach problems that come and go” — he had been started on mesalamine and had accepted the diagnosis and the treatment with the same pragmatic efficiency he applied to everything else. The cramping had largely resolved within six weeks. The fatigue had improved. He had adjusted his diet, reduced his alcohol intake, and continued working his sixty-hour weeks without significant disruption.
He had felt fine for eighteen months. Then his gastroenterologist had done a repeat ileocolonoscopy as part of his two-year follow-up assessment. The endoscopy had shown something his symptom status had not predicted: persistent deep ulcers in the terminal ileum and ascending colon, with transmural inflammation visible on the biopsies. His fecal calprotectin — a stool marker of intestinal inflammation — had been elevated at 680 micrograms per gram (normal under 50). His CRP had been mildly elevated. The colonoscopy had been a more honest account of his disease than his symptoms had been. His gastroenterologist had recommended escalating to adalimumab, an anti-TNF biologic administered by subcutaneous injection every two weeks.
Pedro had been willing to proceed. He trusted his gastroenterologist and had done his own reading about biologics in IBD. His mother Catalina was not convinced.
Catalina Vásquez had come from Monterrey thirty years ago and had worked as a homemaker and then as a childcare provider while raising four children in the Gulfton neighborhood of Houston. She was a practical, observant woman who had managed her family’s health through pragmatic judgment for three decades. She had been at the IBD clinic appointment when the gastroenterologist explained the escalation. Now, at the follow-up appointment with the IBD nurse, Marisol Heredia-Ramos, she asked the question she had been holding since that first conversation.
“Mi hijo se siente bien,” she said. “Lleva dos años tomándo la mesalamina y se siente bien. Si el medicamento funciona y él no siente nada, ¿para qué cambiar a algo más fuerte con más riesgos?” (My son feels well. He has been taking mesalamine for two years and he feels well. If the medication works and he feels nothing, why change to something stronger with more risks?)
Marisol had prepared for this conversation. She drew a simple cross-section diagram of the bowel wall on the paper covering the exam table — a tube in the center representing the lumen, then concentric layers labeled mucosa, submucosa, muscularis propria, serosa. “Para entender por qué la mesalamina no es suficiente en la enfermedad de Crohn, hay que entender la diferencia entre las dos enfermedades,” she said. “Y la diferencia más importante es qué parte del intestino está inflamada.” (To understand why mesalamine is not enough in Crohn’s disease, you need to understand the difference between the two diseases. And the most important difference is which part of the intestine is inflamed.)
She explained that the intestinal wall had several layers. The innermost layer — the mucosa — was the surface the food passed over. The next layers went deeper, into the muscle of the wall, and then into the outer covering. Ulcerative colitis, she said, was a disease of the surface layer only. Like sunburn — the injury was on the skin, and a cream applied to the surface of the skin could reach the injury. Mesalamine was the cream: it worked on the surface of the intestine, where UC lived.
“La enfermedad de Crohn es diferente,” she said. “La inflamación de la enfermedad de Crohn no se queda en la superficie — atraviesa toda la pared del intestino. Como una herida que llega hasta el músculo y el tejido de debajo de la piel, no solo una quemadura superficial. La mesalamina llega a la superficie. No puede llegar a las capas profundas. Aunque Pedro no sienta dolor ni diarrea, las biopsias de la colonoscopía muestran que la inflamación está activa en las capas profundas de la pared del intestino.” (Crohn’s disease is different. The inflammation of Crohn’s disease does not stay on the surface — it goes through the entire wall of the intestine. Like a wound that reaches the muscle and the tissue under the skin, not just a surface burn. Mesalamine reaches the surface. It cannot reach the deep layers. Even though Pedro does not feel pain or diarrhea, the biopsies from the colonoscopy show that the inflammation is active in the deep layers of the intestinal wall.)
Catalina was looking at the diagram. “¿Y qué pasa si la inflamación sigue ahí aunque él no la sienta?” she asked. (And what happens if the inflammation continues there even though he does not feel it?)
“La inflamación profunda y continua hace que la pared del intestino forme cicatrices,” Marisol said. “Con el tiempo, esas cicatrices hacen que el intestino se estreche — eso se llama una estenosis. Una estenosis puede llegar a bloquear el paso de los alimentos, y eso requiere cirugía. O la inflamación puede abrirse paso a través de la pared del intestino hacia afuera y crear un canal anormal entre el intestino y otro órgano o la piel — eso se llama fístula. Todo eso puede ocurrir sin que Pedro sienta nada hasta que el problema ya está avanzado.” (Deep, ongoing inflammation causes the intestinal wall to form scar tissue. Over time, those scars cause the intestine to narrow — that is called a stricture. A stricture can eventually block the passage of food, and that requires surgery. Or the inflammation can break through the intestinal wall outward and create an abnormal channel between the intestine and another organ or the skin — that is called a fistula. All of this can occur without Pedro feeling anything until the problem is already advanced.)
Pedro had been following the explanation carefully. He had the methodical attention of someone reading a project specification. “¿El biológico llega a las capas profundas?” he asked. (Does the biologic reach the deep layers?)
“Sí,” Marisol said. “Los biológicos como el adalimumab funcionan en la sangre. Se inyectan bajo la piel, entran al torrente sanguíneo, y circulan por todo el cuerpo — incluyendo la pared del intestino en todas sus capas. Bloquean una proteína llamada TNF-alfa que es la que activa la inflamación profunda. No es que la mesalamina falle — es que estaba haciendo lo que podía hacer, que era controlar los síntomas en la superficie. El biológico hace lo que la mesalamina no puede hacer.” (Yes. Biologics like adalimumab work in the blood. They are injected under the skin, enter the bloodstream, and circulate throughout the body — including the intestinal wall in all its layers. They block a protein called TNF-alpha that is what activates the deep inflammation. It is not that mesalamine failed — it was doing what it could do, which was controlling the symptoms on the surface. The biologic does what mesalamine cannot do.)
Catalina sat back in her chair. “Entonces sentirse bien no significa que la enfermedad esté bien controlada,” she said slowly. (So feeling well does not mean the disease is well controlled.)
“En la enfermedad de Crohn, no siempre,” Marisol said. “Sentirse bien es importante — significa que los síntomas están controlados, y eso importa para la calidad de vida. Pero la colonoscopía nos dice lo que los síntomas no dicen: si la inflamación real en la pared del intestino está resuelta o sigue activa. Lo que encontramos en la colonoscopía de Pedro dice que la inflamación profunda está activa aunque él no la sienta. El objetivo ahora es resolverla.” (In Crohn’s disease, not always. Feeling well is important — it means the symptoms are controlled, and that matters for quality of life. But the colonoscopy tells us what the symptoms do not say: whether the actual inflammation in the intestinal wall has resolved or is still active. What we found on Pedro’s colonoscopy says the deep inflammation is active even though he does not feel it. The goal now is to resolve it.)
Pedro looked at his mother. “Entendido,” he said. “Los síntomas estaban bien. La enfermedad no.” (Understood. The symptoms were fine. The disease was not.)
Scenario 2: Gloria Ramírez-Santos — 52, librarian from San Antonio, Texas
Gloria Ramírez-Santos had lived with ulcerative colitis for eighteen years, since she had been diagnosed at thirty-four after a two-month episode of bloody diarrhea and cramping that she had initially attributed to a parasitic infection from a trip to Oaxaca. The colonoscopy had found pancolitis — inflammation extending from the rectum through the entire colon — and the biopsies had confirmed UC. She had been managed with mesalamine and periodic short courses of prednisone for flares, and for the past three years she had been in sustained clinical and endoscopic remission on a stable medication regimen. She felt well. Her gastroenterologist’s notes described her as “clinical and endoscopic remission, Mayo score 0, fecal calprotectin 38 micrograms per gram.”
Her gastroenterologist had scheduled her annual surveillance colonoscopy. Her husband Ernesto, who was a retired civil engineer and a methodical man who liked to understand the reasoning behind any recommendation, had a question at the IBD clinic appointment where the surveillance schedule was explained.
“Gloria se siente perfectamente bien,” Ernesto said. “La última colonoscopía fue hace un año y también salió normal. ¿Qué le puede encontrar una colonoscopía este año que no se puede detectar con un análisis de sangre o una consulta clínica? Tiene entendido que hay riesgos de la colonoscopía aunque sean pequeños — ¿para qué un procedimiento si no hay nada que buscar?” (Gloria feels perfectly well. The last colonoscopy was one year ago and was also normal. What can a colonoscopy find this year that cannot be detected with a blood test or a clinical consultation? He understands there are risks to colonoscopy even if they are small — why a procedure when there is nothing to look for?)
The IBD nurse, Patricia Morales-Castellanos, recognized the question as a well-reasoned one. Ernesto was not dismissing the recommendation — he was asking for the clinical logic, and the logic required explanation. “La razón por la que la colonoscopía de vigilancia es importante incluso cuando Gloria se siente bien tiene que ver con un riesgo específico de la colitis ulcerativa de muchos años que no produce síntomas y que no se detecta con análisis de sangre,” she said. “Ese riesgo es el cáncer colorrectal.” (The reason surveillance colonoscopy is important even when Gloria feels well has to do with a specific risk of long-standing ulcerative colitis that produces no symptoms and is not detected by blood tests. That risk is colorectal cancer.)
Ernesto nodded. He had known there was a connection between UC and colon cancer. He had not known the mechanism. “¿Cómo funciona esa relación?” he asked. (How does that relationship work?)
Patricia explained. The lining of the intestine, she said, was made of cells that divided continuously to replace those that were shed as food moved through. Under normal conditions, this rapid cell division was tightly regulated. But in ulcerative colitis, the mucosa experienced repeated cycles of inflammation, injury, and repair over years. Each cycle of inflammation produced free radicals — chemically reactive molecules from the activated immune cells fighting the inflammation — that damaged the DNA of the rapidly dividing epithelial cells. Most of that DNA damage was repaired correctly. But some was not, and accumulated incorrectly repaired DNA damage — over years and decades of repeated inflammatory cycles — could produce cells whose growth regulation was disrupted.
“Ese proceso,” she said, “se llama displasia — células que empiezan a crecer de manera desorganizada pero que todavía no son cáncer. La displasia es el paso previo al cáncer colorrectal. Y el problema central que hace necesaria la vigilancia es este: la displasia no produce ningún síntoma. No hay dolor. No hay sangre en las heces. No hay nada que Gloria pueda sentir que le indique que está ocurriendo.” (That process is called dysplasia — cells that begin to grow in a disorganized way but are not yet cancer. Dysplasia is the step prior to colorectal cancer. And the central problem that makes surveillance necessary is this: dysplasia produces no symptoms. No pain. No blood in the stool. Nothing that Gloria can feel that would indicate it is occurring.)
Ernesto was listening with the focused attention of someone taking in technical specifications. “¿Y la displasia se puede ver en la colonoscopía?” he asked. (And can dysplasia be seen on colonoscopy?)
“Ese es exactamente el punto,” Patricia said. “Muchas veces, no. La displasia en la colitis ulcerativa puede ocurrir en mucosa que parece completamente normal a simple vista — que el endoscopista ve rosada, brillante, sin ninguna irregularidad visible. La única manera de detectarla es tomando muestras de tejido en puntos sistémicos del intestino durante la colonoscopía y analizando esas muestras al microscopio. Así que la colonoscopía de vigilancia en la colitis ulcerativa no es para buscar algo que se ve — es para tomar muestras de tejido que pueden mostrar cambios que no se ven.” (That is exactly the point. Many times, no. Dysplasia in ulcerative colitis can occur in mucosa that appears completely normal to the naked eye — that the endoscopist sees as pink, shiny, with no visible irregularities. The only way to detect it is by taking tissue samples at systematic points in the intestine during colonoscopy and analyzing those samples under the microscope. So surveillance colonoscopy in ulcerative colitis is not to look for something that is visible — it is to take tissue samples that can show changes that are not visible.)
She added the risk context. Patients with long-standing extensive UC — pancolitis or left-sided colitis of more than eight to ten years — had a colorectal cancer risk approximately two to five times higher than the general population, with risk increasing as the duration of disease lengthened. Gloria had had pancolitis for eighteen years. Without surveillance, any dysplasia that developed would not be detected until it progressed to invasive cancer and produced symptoms — by which time treatment options and outcomes were significantly worse.
“La mamografía es un buen paralelo,” Patricia said. “Las mujeres se hacen mamografías aunque no sientan nada, aunque se palpen el pecho cada mes y no encuentren nada. Porque el cáncer de mama temprano tampoco produce síntomas, y la mamografía puede encontrarlo cuando todavía es tratable. La colonoscopía de vigilancia en la colitis ulcerativa funciona igual: busca el cambio antes de que el cambio sea sintomtático, porque cuando es sintomtático ya es cáncer.” (Mammography is a good parallel. Women get mammograms even though they feel nothing, even though they palpate their breasts every month and find nothing. Because early breast cancer also produces no symptoms, and mammography can find it when it is still treatable. Surveillance colonoscopy in ulcerative colitis works the same way: it looks for the change before the change is symptomatic, because when it is symptomatic it is already cancer.)
Ernesto sat back. “Entendido,” he said. “Los síntomas que ella tiene no son lo que se está vigilando. Se está vigilando algo que ocurre por debajo de los síntomas.” (Understood. The symptoms she has are not what is being monitored. What is being monitored is something that occurs below the symptoms.)
“Exactamente,” Patricia said. “Y que él riesgo exista no significa que sea probable que encuentren displasia en esta colonoscopía — la mayoría de las colonoscopías de vigilancia en pacientes bien controlados como Gloria son negativas. Pero el valor de la colonoscopía está justamente en los casos en los que sí hay un cambio: encontrarlo temprano cambia completamente el resultado.” (Exactly. And the fact that the risk exists does not mean it is probable that they will find dysplasia on this colonoscopy — the majority of surveillance colonoscopies in well-controlled patients like Gloria are negative. But the value of colonoscopy is precisely in the cases where there is a change: finding it early completely changes the outcome.)
Gloria had been listening to her husband and the nurse with a quiet alertness. She had understood the surveillance logic before. Hearing it explained clearly to Ernesto made it easier to explain to her sisters, who asked the same question every year. “Ahora ya lo puedo explicar yo,” she said. (Now I can explain it myself.)
Scenario 3: Carlos Mejía-Fernández — 44, high school teacher from Phoenix, Arizona
Carlos Mejía-Fernández taught AP Biology and Environmental Science at a high school in west Phoenix, and he had managed Crohn’s disease for seven years. The disease had been reasonably well controlled on azathioprine, with one flare two years after diagnosis and a second, more significant one three months ago. The second flare — severe abdominal cramping, six to eight loose stools per day, unintentional weight loss of eight pounds over four weeks — had been treated with prednisone 40 mg per day. After four weeks of prednisone, the flare had resolved completely. His symptoms were gone. He was eating normally. He had returned to work. His gastroenterologist had given him a tapering schedule: reduce prednisone by 5 mg per week over eight weeks.
Three days after starting the taper, Carlos had called the IBD clinic. He had been on prednisone before and remembered the side effects: insomnia, the restlessness in his legs at night, eating more than he wanted, a feeling of mental hyperactivity that made it hard to grade papers in the evening. He felt completely well now that the flare was controlled. He wanted to know if he could stop the prednisone now instead of tapering over eight weeks.
The IBD nurse, Rosa Jiménez-Vargas, took the call. Carlos’s sister Isabel — who worked as a medical assistant in an orthopedic office and had some clinical knowledge — was also on the line. Isabel had told Carlos that since the Crohn’s was resolved, the prednisone should be fine to stop.
“Carlos se siente perfectamente,” Isabel said. “La colitis está en remisión. ¿Por qué continuar la prednisona si ya hizo su trabajo?” (Carlos feels perfectly well. The colitis is in remission. Why continue prednisone if it has already done its job?)
Rosa recognized the gap in understanding. She had had this conversation — or close to it — many times. “Entiendo perfectamente la lógica,” she said, “y tiene sentido: la enfermedad que requirió la prednisona está controlada, entonces ¿para qué seguir tomando un medicamento con efectos secundarios que Carlos ya no necesita? Pero hay un problema, y es que la prednisona hizo algo al cuerpo además de controlar la inflamación del Crohn. Y ese algo no se resolvió cuando se resolvió la inflamación.” (I understand the logic completely, and it makes sense: the disease that required the prednisone is controlled, so why continue taking a medication with side effects that Carlos no longer needs? But there is a problem, and it is that prednisone did something to the body in addition to controlling the Crohn’s inflammation. And that something did not resolve when the inflammation resolved.)
She asked Carlos if he knew what cortisol was. He did — he taught biology, and he knew the basics: a stress hormone from the adrenal glands. “Bien,” Rosa said. “El cortisol no es solo para el estrés. El cuerpo lo necesita todo el tiempo, en niveles pequeños pero continuos, para funciones básicas: mantener la presión arterial estable, regular el azúcar en sangre en ayunas, controlar los electrolitos, y dar al cuerpo la capacidad de responder si hay una infección o una lesión. Es una hormona que trabaja todo el tiempo, no solo cuando hay estrés.” (Good. Cortisol is not only for stress. The body needs it all the time, at small but continuous levels, for basic functions: maintaining stable blood pressure, regulating fasting blood sugar, controlling electrolytes, and giving the body the capacity to respond if there is an infection or injury. It is a hormone that works all the time, not only when there is stress.)
She explained the regulatory system. Normally, the brain — specifically a structure called the hypothalamus — sent a signal to the pituitary gland, which then sent a signal to the adrenal glands, which made and released cortisol. It was a three-step chain of command: hypothalamus, pituitary, adrenal cortex. The adrenal glands received their orders from above. When the cortisol level in the blood was sufficient, the cortisol itself told the hypothalamus and the pituitary to stop sending signals — a negative feedback loop that kept the system in balance.
“La prednisona,” she continued, “funciona en el cuerpo igual que el cortisol propio. Cuando Carlos tomó 40 mg de prednisona por día durante cuatro semanas, su hipotálamo y su hipófisis recibieron una señal continua diciendo ‘ya hay suficiente cortisol en la sangre — no mandes más órdenes.’ Y obedecieron. Dejaron de mandar la señal a las glándulas suprarrenales. Y las glándulas suprarrenales, sin la señal de arriba, dejaron de producir cortisol propio.” (Prednisone works in the body the same as endogenous cortisol. When Carlos took 40 mg of prednisone per day for four weeks, his hypothalamus and pituitary received a continuous signal saying “there is already enough cortisol in the blood — do not send more orders.” And they obeyed. They stopped sending the signal to the adrenal glands. And the adrenal glands, without the signal from above, stopped producing their own cortisol.)
Isabel had been listening carefully. “¿Y ahora no pueden producirlo de inmediato si se para la prednisona?” she asked. (And now they cannot produce it immediately if prednisone is stopped?)
“Exactamente,” Rosa said. “Las glándulas suprarrenales necesitan tiempo — varios días a semanas — para volver a funcionar a plena capacidad después de un período de inactividad. Si Carlos para la prednisona hoy, mañana su cuerpo no tiene cortisol propio suficiente porque las glándulas todavía no recibieron la señal de volver a trabajar durante suficiente tiempo. Y bajo condiciones normales, eso puede que no cause más que cansancio, náuseas, y presión arterial un poco baja — que es molesto pero manejable. El problema real es si hay algún estrés fisiológico mientras las glándulas se están recuperando.” (Exactly. The adrenal glands need time — several days to weeks — to return to full capacity after a period of inactivity. If Carlos stops prednisone today, tomorrow his body does not have enough endogenous cortisol because the glands have not yet received the signal to return to work for long enough. And under normal daily conditions, that may cause no more than fatigue, nausea, and slightly low blood pressure — which is unpleasant but manageable. The real problem is if there is any physiological stress while the glands are recovering.)
Carlos was following this with the methodical attention of a biology teacher encountering a mechanism he had taught in simplified form. “¿Qué tipo de estrés?” he asked. (What kind of stress?)
“Una infección — aunque sea un resfriado fuerte. Una lesión, un accidente. Una cirugía. Cualquier situación en la que el cuerpo normalmente triplicaría o cuadruplicaría su producción de cortisol para manejar el estrés,” Rosa said. “Si las glándulas suprarrenales no pueden hacer eso porque todavía están recuperando su capacidad, el cuerpo no puede responder adecuadamente. La presión arterial puede caer. Puede haber confusión. Puede ser una emergencia médica — lo que se llama una crisis suprarrenal. En los hospitales, cuando alguien que ha estado en esteroides llega con una infección grave, uno de los primeros pasos es darle cortisol intravenoso porque se sabe que sus glándulas pueden no poder responder solas.” (An infection — even a strong cold. An injury, an accident. A surgery. Any situation in which the body would normally triple or quadruple its cortisol production to manage the stress. If the adrenal glands cannot do that because they are still recovering their capacity, the body cannot respond adequately. Blood pressure may fall. There may be confusion. It can be a medical emergency — what is called an adrenal crisis. In hospitals, when someone who has been on steroids arrives with a severe infection, one of the first steps is to give intravenous cortisol because it is known that their glands may not be able to respond on their own.)
Isabel was quiet for a moment. She had seen steroid-dependent patients at the orthopedic office and had known there was a clinical reason for tapering, but had not understood the mechanism precisely. “No sabía que era por las glándulas suprarrenales,” she said. “Pensé que el taper era para evitar un rebote del Crohn.” (I did not know it was because of the adrenal glands. I thought the taper was to prevent a Crohn’s rebound.)
“El rebound también puede ocurrir si se para de golpe,” Rosa said, “pero el eje suprarrenal es el motivo más importante del taper después de un curso de prednisona de varias semanas. La enfermedad de Crohn de Carlos está controlada — eso es una buena noticia y es exactamente lo que queríamos. Pero las glándulas suprarrenales tienen su propio calendario de recuperación, que no está ligado a cómo se siente Carlos del Crohn.” (Rebound can also occur if stopped abruptly, but the adrenal axis is the most important reason for tapering after a multi-week prednisone course. Carlos’s Crohn’s disease is controlled — that is good news and exactly what we wanted. But the adrenal glands have their own recovery timeline, which is not linked to how Carlos feels with regard to the Crohn’s.)
Carlos absorbed this. “Son dos cosas distintas que ocurren al mismo tiempo con el mismo medicamento,” he said. “El Crohn se mejoró con la prednisona, y eso ya está resuelto. Pero la prednisona también suprimió las glándulas suprarrenales, y eso todavía no está resuelto.” (They are two different things happening at the same time with the same medication. The Crohn’s improved with prednisone, and that is already resolved. But the prednisone also suppressed the adrenal glands, and that is not yet resolved.)
“Exacto,” Rosa said. “El taper resuelve la segunda parte. Son ocho semanas — y puede ser que el efecto de los esteroides en el sueño y el apetito mejore bastante con las dosis más bajas en las primeras semanas. La mayoría de los pacientes notan que las semanas finales del taper son muy tolerables.” (Exactly. The taper resolves the second part. It is eight weeks — and it may be that the effect of steroids on sleep and appetite improves considerably with the lower doses in the first weeks. Most patients notice that the final weeks of the taper are very tolerable.)
Carlos agreed to follow the taper schedule. Before ending the call, he asked one more question. “¿Y si tengo fiebre o algo así en estas ocho semanas?” (And if I have a fever or something like that during these eight weeks?)
“Llame inmediatamente,” Rosa said. “Con fiebre o cualquier infección significativa mientras está en el taper, tenemos que aumentar la dosis de prednisona temporalmente — lo que se llama la ‘dosis de estrés’ — para compensar lo que las glándulas todavía no pueden hacer solas. Es importante que lo sepa.” (Call immediately. With fever or any significant infection while on the taper, we need to temporarily increase the prednisone dose — what is called the “stress dose” — to compensate for what the glands cannot yet do on their own. It is important for you to know this.)
Eight practical phrases for IBD clinic nurses
- Explaining why mesalamine does not treat Crohn’s disease: “La mesalamina actúa en la superficie del intestino. Es muy buena para la colitis ulcerativa, que es una enfermedad que se queda en la capa superficial. Pero la enfermedad de Crohn inflama toda la pared del intestino — desde la superficie hasta el músculo más profundo. La mesalamina no llega tan profundo. Aunque los síntomas estén controlados, la inflamación profunda puede seguir activa y seguir haciendo daño.” (Mesalamine acts on the surface of the intestine. It is very good for ulcerative colitis, which is a disease that remains in the superficial layer. But Crohn’s disease inflames the entire intestinal wall — from the surface to the deepest muscle. Mesalamine does not reach that deep. Even if symptoms are controlled, the deep inflammation can continue to be active and continue causing damage.)
- Explaining what a biologic does in Crohn’s disease: “Los biológicos como el adalimumab o el infliximab se inyectan o infunden, entran a la sangre y circulan por todo el cuerpo. En la sangre, bloquean una proteína que se llama TNF-alfa, que es la que manda la señal de inflamación a todas las capas de la pared del intestino. Al bloquear esa señal, la inflamación profunda se puede resolver — algo que la mesalamina no puede hacer porque no llega a donde está esa señal.” (Biologics like adalimumab or infliximab are injected or infused, enter the blood, and circulate throughout the body. In the blood, they block a protein called TNF-alpha, which is what sends the inflammation signal to all layers of the intestinal wall. By blocking that signal, deep inflammation can resolve — something mesalamine cannot do because it does not reach where that signal is.)
- Explaining the difference between clinical remission and mucosal healing in Crohn’s: “Sentirse bien significa que los síntomas están controlados — y eso importa mucho para la calidad de vida. Pero en la enfermedad de Crohn, la inflamación puede seguir activa en las capas profundas de la pared del intestino sin producir síntomas. La colonoscopia nos dice si la inflamación realmente se resolvió o si sigue activa por debajo de los síntomas. El objetivo del tratamiento ahora es resolverla por completo, porque la inflamación que queda produce cicatrices que pueden estrechar el intestino con el tiempo.” (Feeling well means the symptoms are controlled — and that matters greatly for quality of life. But in Crohn’s disease, inflammation can continue to be active in the deep layers of the intestinal wall without producing symptoms. The colonoscopy tells us whether the inflammation truly resolved or is still active below the symptom threshold. The treatment goal now is to resolve it completely, because the remaining inflammation causes scarring that can narrow the intestine over time.)
- Explaining why UC surveillance colonoscopy is required when asymptomatic: “La colitis ulcerativa de muchos años puede causar que las células del intestino desarrollen cambios microscópicos — llamados displasia — que no producen síntomas y que no se ven a simple vista. Esos cambios son el paso previo al cáncer de colon. La única manera de encontrarlos antes de que avancen es tomar muestras de tejido del intestino durante la colonoscopia, aunque todo se vea normal. Esperar los síntomas para hacerla sería esperar a que el cáncer ya esté establecido.” (Long-standing ulcerative colitis can cause intestinal cells to develop microscopic changes — called dysplasia — that produce no symptoms and cannot be seen with the naked eye. Those changes are the step prior to colon cancer. The only way to find them before they progress is to take tissue samples from the intestine during colonoscopy, even if everything appears normal. Waiting for symptoms before doing it would be waiting until the cancer is already established.)
- Explaining the cancer risk in long-standing extensive UC: “Las personas con colitis ulcerativa extensa — que afecta la mayor parte del colon — de muchos años tienen entre dos y cinco veces más probabilidad de desarrollar cáncer colorrectal que la población general. Ese riesgo aumenta cuantos más años lleva la enfermedad. La vigilancia con colonoscopia cada uno a dos años es la herramienta que existe para detectar el cambio antes de que se vuelva cáncer. En los pacientes que hacen la vigilancia regularmente, cuando se encuentra algo se puede tratar en una etapa muy temprana.” (People with extensive ulcerative colitis — affecting most of the colon — of many years have two to five times greater probability of developing colorectal cancer than the general population. That risk increases the more years the disease has been present. Annual or biennial surveillance colonoscopy is the tool that exists to detect the change before it becomes cancer. In patients who do regular surveillance, when something is found it can be treated at a very early stage.)
- Explaining HPA axis suppression to a patient on prednisone: “La prednisona funciona como el cortisol propio del cuerpo. Cuando la prednisona está en la sangre, el cerebro le dice a las glándulas suprarrenales ‘no necesito que produzcan más cortisol — ya hay suficiente.’ Después de semanas de prednisona, las glándulas suprarrenales necesitan tiempo para volver a producir cortisol por su cuenta. Si se para la prednisona de golpe, el cuerpo se queda sin cortisol suficiente hasta que las glándulas se recuperen.” (Prednisone works like the body’s own cortisol. When prednisone is in the blood, the brain tells the adrenal glands “I do not need you to produce more cortisol — there is already enough.” After weeks of prednisone, the adrenal glands need time to start producing cortisol on their own again. If prednisone is stopped abruptly, the body is left without enough cortisol until the glands recover.)
- Explaining why cortisol is essential: “El cortisol no es solo para el estrés agudo. El cuerpo lo necesita de forma continua para mantener la presión arterial estable, regular el azúcar en sangre, controlar el sodio y el potasio, y responder ante infecciones o lesiones. Sin cortisol suficiente, esas funciones básicas se alteran. Por eso se baja la prednisona poco a poco — para dar tiempo a que las glándulas suprarrenales recuperen su capacidad de producir cortisol propio antes de que la prednisona desaparezca completamente.” (Cortisol is not only for acute stress. The body needs it continuously to maintain stable blood pressure, regulate blood sugar, control sodium and potassium, and respond to infections or injuries. Without enough cortisol, those basic functions are disrupted. That is why prednisone is lowered gradually — to give the adrenal glands time to recover their capacity to produce their own cortisol before prednisone disappears completely.)
- Explaining the stress-dose rule to a patient on a steroid taper: “Mientras sigue bajando la dosis de prednisona, si hay fiebre, infección, cirugía, o cualquier situación que normalmente sea muy estresante para el cuerpo, hay que llamar al médico ese mismo día. Es posible que se necesite aumentar la dosis temporalmente — una dosis de estrés — porque en esas situaciones el cuerpo normalmente produce mucho más cortisol del que produce en un día normal, y las glándulas todavía no pueden hacer eso solas. No es un fracaso del taper — es una precaución normal durante la recuperación.” (While the prednisone dose is still being lowered, if there is fever, infection, surgery, or any situation that is normally very stressful for the body, call the doctor that same day. It may be necessary to temporarily increase the dose — a stress dose — because in those situations the body normally produces much more cortisol than it produces on a normal day, and the glands cannot yet do that on their own. It is not a failure of the taper — it is a normal precaution during recovery.)
FAQs: IBD, Spanish-speaking patients, and IBD nursing communication
How do IBD clinic nurses explain to a Spanish-speaking patient’s family why Crohn’s disease requires a biologic rather than mesalamine when symptoms are controlled?
Mesalamine (5-aminosalicylic acid) inhibits cyclo-oxygenase and 5-lipoxygenase in the colonic mucosal epithelium, reducing prostaglandin E2 and leukotriene B4 synthesis at the luminal surface — a mechanism effective for ulcerative colitis because UC inflammation is confined to the mucosa and submucosa. Crohn’s disease is transmural: TNF-alpha, IL-12, and IL-23 secreted by activated macrophages and CD4+ T cells (Th1 and Th17 lineages) drive full-thickness bowel wall inflammation extending through the muscularis propria into the serosa. Mesalamine’s topical mechanism cannot reach this process. Symptom control without mucosal healing allows transmural fibrotic remodeling to continue, eventually producing strictures (bowel lumen narrowing, obstructive symptoms) and fistulas (abnormal transmural channels to adjacent bowel, bladder, or skin). Modern IBD guidelines target mucosal healing — endoscopic normalization of the mucosa with resolved deep inflammation — not symptom control alone, because mucosal healing is associated with dramatically lower long-term complication rates. Anti-TNF biologics reach the transmural inflammatory process through the systemic circulation. The Spanish frame: “La mesalamina llega a la superficie del intestino y no más profundo. En la enfermedad de Crohn la inflamación atraviesa toda la pared — el biológico llega a esa inflamación profunda a través de la sangre y la detiene.”
How do IBD clinic nurses explain to a Spanish-speaking patient’s family why ulcerative colitis surveillance colonoscopy is required when the patient has been asymptomatic for years?
UC-associated colorectal cancer arises through a distinct pathway from sporadic CRC. Chronic mucosal inflammation produces recurring oxidative DNA damage in the rapidly dividing crypt epithelial cells; accumulated mutations in mismatch repair genes, tumor suppressor genes (APC, TP53), and oncogenes (KRAS) drive dysplastic transformation over years to decades. Crucially, this dysplasia is endoscopically occult — it develops in mucosa that appears normal on visual inspection — and produces no symptoms until progression to invasive adenocarcinoma. Patients with long-standing extensive UC (pancolitis or left-sided colitis >8 years) have a 2–5× elevated CRC risk compared to the general population, increasing with disease duration. Surveillance colonoscopy with systematic 4-quadrant biopsies every 10 cm samples enough colonic mucosa to detect dysplasia as a microscopic pre-invasive change, before it has progressed to invasive cancer. Clinical remission does not eliminate the surveillance indication because remission is a symptom and endoscopy endpoint, not a histological endpoint for dysplastic risk. The Spanish frame: “La colitis ulcerativa de muchos años produce cambios celulares microscópicos que no se sienten y no se ven. La colonoscopia con biopsias es la única forma de detectarlos antes de que se vuelvan cáncer.”
How do IBD clinic nurses explain to a Spanish-speaking patient’s family why prednisone must be tapered and cannot be stopped immediately when the IBD flare has resolved?
The reason for tapering is not the IBD but the HPA axis. Exogenous glucocorticoids at supraphysiologic doses (standard IBD flare course: prednisone 40 mg/day, approximately 8 times physiologic daily cortisol equivalents) suppress CRH secretion from the hypothalamus and ACTH secretion from the anterior pituitary through glucocorticoid receptor-mediated negative feedback. Without ACTH stimulation, the adrenal cortex’s steroidogenic machinery is downregulated and zona fasciculata cells partially atrophy after 2–4 weeks. Cortisol is required continuously for vascular smooth muscle tone, renal sodium handling, fasting glucose regulation, and the amplified cortisol response to physiological stressors (infection, injury, surgery) that is essential for hemodynamic stability. Abrupt discontinuation after a 4-week course leaves the patient transiently cortisol-deficient; under basal conditions this produces fatigue and mild hypotension; under physiological stress it can precipitate adrenal crisis (refractory hypotension, hyponatremia, hyperkalemia, altered consciousness). The taper (5–10 mg reduction per week) allows HPA axis recovery to parallel steroid withdrawal. Disease remission and adrenal recovery are independent: feeling well from Crohn’s does not indicate that the adrenal glands have restored cortisol-producing capacity. The Spanish frame: “Que el Crohn esté controlado y que las glándulas suprarrenales hayan recuperado su capacidad son dos cosas distintas que ocurren en tiempos distintos. El taper resuelve la segunda.”
How do IBD clinic nurses explain the difference between clinical remission and mucosal healing to Spanish-speaking patients with Crohn’s disease?
Clinical remission (no or minimal symptoms, normal CDAI, no blood in stool) is the patient’s subjective experience of disease control. Mucosal healing is an endoscopic and histological endpoint: normalization of the mucosal appearance (no active ulcers, no deep erosions, no significant edema) and resolution of transmural inflammation on biopsies. These endpoints often co-occur but are not equivalent. A patient with Crohn’s disease can be in clinical remission with active endoscopic and histological inflammation — because Crohn’s symptoms are variably coupled to mucosal status, and patients differ in their symptom threshold. Long-term outcome data consistently show that patients achieving mucosal healing have lower rates of stricture formation, fistula development, hospitalization, and surgery over 5–10 years compared to patients achieving clinical remission without mucosal healing, because the transmural inflammation that persists below the symptom threshold continues to drive fibrotic remodeling. Modern treat-to-target guidelines use objective markers (mucosal healing on endoscopy, fecal calprotectin normalization, CRP normalization) rather than symptom control as the treatment target. The Spanish frame: “Sentirse bien es necesario pero no suficiente para saber si la enfermedad está realmente controlada. El objetivo es que la inflamación profunda también se resuelva, no solo los síntomas.”
What are the key Spanish phrases IBD clinic nurses use when explaining Crohn’s disease, UC surveillance, and corticosteroid tapering to Spanish-speaking patients?
Four recurring communication moments where precise language consistently matters. When explaining why mesalamine is insufficient in Crohn’s: “La mesalamina llega a la superficie del intestino pero no a las capas profundas. En la enfermedad de Crohn, la inflamación atraviesa toda la pared del intestino — la mesalamina no puede llegar a donde está la inflamación que causa las complicaciones más graves como el estrechamiento o las fístulas.” (Mesalamine reaches the surface of the intestine but not the deep layers. In Crohn’s disease, inflammation goes through the entire intestinal wall — mesalamine cannot reach where the inflammation that causes the most serious complications like strictures or fistulas is.) When explaining UC surveillance: “La colitis ulcerativa de muchos años aumenta el riesgo de cáncer de colon. El cambio que lo anuncia — la displasia — no produce síntomas y no se ve a simple vista. Solo se detecta tomando pequeñas muestras del intestino durante la colonoscopia. La colonoscopia de vigilancia no es porque Gloria esté mal — es porque el cáncer de colon se puede evitar si se detecta el cambio temprano.” (Long-standing ulcerative colitis increases colon cancer risk. The change that announces it — dysplasia — produces no symptoms and cannot be seen with the naked eye. It is only detected by taking small samples from the intestine during colonoscopy. Surveillance colonoscopy is not because Gloria is doing poorly — it is because colon cancer can be prevented if the change is detected early.) When explaining the prednisone taper: “La prednisona suprime las glándulas que hacen el cortisol propio del cuerpo. Después de cuatro semanas a dosis alta, esas glándulas necesitan semanas para recuperarse. Si se para de un día para otro, el cuerpo puede no tener cortisol suficiente — especialmente si hay una infección o una situación de estrés. La bajada gradual da tiempo para que el cuerpo se recupere.” (Prednisone suppresses the glands that make the body’s own cortisol. After four weeks at high doses, those glands need weeks to recover. If stopped from one day to the next, the body may not have enough cortisol — especially if there is an infection or a stressful situation. The gradual reduction gives the body time to recover.) When explaining treat-to-target in Crohn’s: “El objetivo del tratamiento no es solo que se sienta bien — es que la colonoscopia y los análisis también confirmen que la inflamación está resuelta. Eso es lo que protege de las complicaciones a largo plazo. Los síntomas y la inflamación no siempre van juntos en la enfermedad de Crohn.” (The treatment goal is not only to feel well — it is for the colonoscopy and lab tests to also confirm that inflammation has resolved. That is what protects against long-term complications. Symptoms and inflammation do not always go together in Crohn’s disease.)